CFTR modulators may decrease episodes of pancreatitis among individuals with CF with residual pancreatic function (Carrion et al., 2018) and significantly reduce pulmonary exacerbations even in patients without early lung function improvement (McColley et al., 2019). The gene discussed is CFTR; the disease is pancreatitis.